177 related articles for article (PubMed ID: 22498006)
1. Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis.
Mishra N; Buelens K; Theyskens S; Compernolle G; Gils A; Declerck PJ
J Thromb Haemost; 2012 Jun; 10(6):1091-9. PubMed ID: 22498006
[TBL] [Abstract][Full Text] [Related]
2. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
[TBL] [Abstract][Full Text] [Related]
3. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.
Schneider M; Boffa M; Stewart R; Rahman M; Koschinsky M; Nesheim M
J Biol Chem; 2002 Jan; 277(2):1021-30. PubMed ID: 11684677
[TBL] [Abstract][Full Text] [Related]
4. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
Foley JH; Kim P; Nesheim ME
J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo application.
Hendrickx ML; Zatloukalova M; Hassanzadeh-Ghassabeh G; Muyldermans S; Gils A; Declerck PJ
J Thromb Haemost; 2014 Feb; 12(2):229-36. PubMed ID: 24354544
[TBL] [Abstract][Full Text] [Related]
6. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation.
Zhou X; Declerck PJ
J Thromb Haemost; 2015 Jun; 13(6):1084-9. PubMed ID: 25773535
[TBL] [Abstract][Full Text] [Related]
7. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis.
Schneider M; Nesheim M
J Thromb Haemost; 2003 Jan; 1(1):147-54. PubMed ID: 12871552
[TBL] [Abstract][Full Text] [Related]
8. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor.
Buelens K; Hassanzadeh-Ghassabeh G; Muyldermans S; Gils A; Declerck PJ
J Thromb Haemost; 2010 Jun; 8(6):1302-12. PubMed ID: 20180900
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability.
Ceresa E; De Maeyer M; Jonckheer A; Peeters M; Engelborghs Y; Declerck PJ; Gils A
J Thromb Haemost; 2007 Oct; 5(10):2105-12. PubMed ID: 17666015
[TBL] [Abstract][Full Text] [Related]
10. Insights into thrombin activatable fibrinolysis inhibitor function and regulation.
Foley JH; Kim PY; Mutch NJ; Gils A
J Thromb Haemost; 2013 Jun; 11 Suppl 1():306-15. PubMed ID: 23809134
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M
J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
[TBL] [Abstract][Full Text] [Related]
12. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
Boffa MB; Wang W; Bajzar L; Nesheim ME
J Biol Chem; 1998 Jan; 273(4):2127-35. PubMed ID: 9442053
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation.
Marx PF; Brondijk TH; Plug T; Romijn RA; Hemrika W; Meijers JC; Huizinga EG
Blood; 2008 Oct; 112(7):2803-9. PubMed ID: 18559974
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase.
Valnickova Z; Thøgersen IB; Potempa J; Enghild JJ
J Biol Chem; 2007 Feb; 282(5):3066-76. PubMed ID: 17138567
[TBL] [Abstract][Full Text] [Related]
15. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)--a comparative study assessing the biological equivalence of rat, murine and human TAFI.
Hillmayer K; Macovei A; Pauwels D; Compernolle G; Declerck PJ; Gils A
J Thromb Haemost; 2006 Nov; 4(11):2470-7. PubMed ID: 17002650
[TBL] [Abstract][Full Text] [Related]
16. Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin.
Marar TT; Boffa MB
J Thromb Haemost; 2016 Apr; 14(4):772-83. PubMed ID: 26816270
[TBL] [Abstract][Full Text] [Related]
17. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A
J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody.
Hendrickx ML; Zatloukalova M; Hassanzadeh-Ghassabeh G; Muyldermans S; Gils A; Declerck PJ
Thromb Haemost; 2014 May; 111(5):824-32. PubMed ID: 24402608
[TBL] [Abstract][Full Text] [Related]
19. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor.
Plug T; Meijers JC
J Thromb Haemost; 2016 Apr; 14(4):633-44. PubMed ID: 26786060
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity.
Zhao L; Buckman B; Seto M; Morser J; Nagashima M
J Biol Chem; 2003 Aug; 278(34):32359-66. PubMed ID: 12799375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
